Browse the evidence

GLP-1RAs appear to be safe and effective in patients with inflammatory bowel disease (IBD).

Healthcare providers can consider GLP-1RAs as a treatment option for IBD patients.

GLP-1RA users demonstrated significantly reduced pseudarthrosis rates at all time points: 6 months (8% vs. 12%; OR=0.702), 12 months (OR=0.730), and 24 months postoperatively (OR=0.788).

GLP-1RAs may be beneficial in reducing complications like pseudarthrosis in ACDF patients.

Semaglutide significantly reduced the risk of major limb events (LEs) compared with control interventions, with an odds ratio of 0.70 (95% CI 0.60–0.82; P < 0.0001).

Semaglutide may be an effective treatment option for reducing the risk of PAD-related complications in patients with diabetes or obesity.

The protective effect of semaglutide on limb events was consistent across patient subgroups, including those with diabetes and obesity.

Semaglutide can be considered for diverse populations at risk of PAD.

Treatment with tesamorelin led to marked reductions in waist circumference and improved lipid levels in a patient with nonobese visceral adiposity.

Tesamorelin may be an effective treatment for reducing visceral fat in specific HIV patients.

Glucagon-like peptide (GLP-1) receptor agonists may induce generalized weight loss but may not effectively target visceral abdominal fat.

GLP-1 receptor agonists may not be the best choice for targeting visceral fat in HIV patients.

1-year treatment persistence among individuals without diabetes initiating high-potency, weight loss-indicated GLP-1RA products increased from 33.2% in 2021 to 60.9% in 1H 2024.

Practitioners should note the significant improvement in treatment persistence, which may indicate better patient adherence and management strategies.

Semaglutide 1-year persistence rates increased from 33.2% in 2021 to 58.6% in 1H 2024.

The increase in semaglutide persistence suggests improved patient adherence, which may be beneficial for weight management strategies.

Tirzepatide 1-year persistence rates were 64.0% in 2023 and 64.8% in 1H 2024.

The high persistence rates for tirzepatide indicate its potential effectiveness and acceptance among patients for weight management.

Bariatric surgery demonstrates durability of outcomes over decades, while pharmacotherapy often requires lifelong administration to maintain weight loss.

Bariatric surgery may provide more sustainable weight loss results compared to medications.

GLP-1 receptor agonists (GLP-1RAs) have substantial new evidence supporting their use in managing endocrine disorders.

Clinicians should consider the new evidence on GLP-1RAs for managing various endocrine disorders.

Liraglutide treatment improved glycaemia as indicated by decreased C-peptide levels.

Liraglutide may help improve blood sugar levels in patients with type 2 diabetes.

Antiobesity medications require long-term use to prevent weight regain.

Practitioners should emphasize the importance of ongoing medication adherence for effective weight management.

Physicians must stay updated with the latest knowledge to enhance glycemic control and mitigate long-term complications.

Continuous education is essential for improving patient outcomes in diabetes care.

GLP-1 receptor agonists (RAs) have revolutionized treatment for type 2 diabetes mellitus and its comorbidities, including obesity and cardiovascular disease.

GLP-1 RAs should be considered as a treatment option for managing type 2 diabetes and associated conditions.

GLP-1 receptor agonists show promising results in men, improving erectile function, testosterone levels, and sperm parameters.

Practitioners may consider GLP-1 receptor agonists as a potential treatment option for men experiencing erectile dysfunction.

GLP-1 receptor agonists enhance insulin secretion, support weight loss, and exhibit neuroprotective and cardiovascular benefits.

Practitioners can consider GLP-1 receptor agonists for their multifaceted benefits in diabetes management.

GLP-1RA use was associated with a lower risk of major adverse cardiovascular events (MACE) in nondiabetic patients with PAD (HR: 0.61; 95% CI: 0.57–0.66; p < 0.001).

GLP-1RAs may be beneficial for reducing cardiovascular risks in patients with PAD who do not have diabetes.

Tirzepatide helps lower blood sugar levels in patients with type 2 diabetes mellitus.

Tirzepatide can be considered for managing blood sugar levels in type 2 diabetes.

GLP-1 receptor agonists reduced major adverse cardiovascular events (MACE) by 31% in Asians.

GLP-1RAs may provide significant cardiovascular benefits for Asian populations.

GLP-1/dual agonists were associated with a 54% lower incidence of physician-reported sleep apnea (PRSA).

Practitioners may consider GLP-1/dual agonists as a treatment option to reduce the incidence of sleep apnea in patients with obesity and type 2 diabetes.

Liraglutide, dulaglutide, semaglutide, and tirzepatide individually reduced the incidence of PRSA compared to the reference arm.

Each GLP-1/dual agonist may be effective in reducing sleep apnea incidence, offering multiple treatment options.

There was a 79% lower incidence of positive airway pressure reports in the GLP-1/dual agonist group compared to controls.

The use of GLP-1/dual agonists may lead to fewer patients requiring positive airway pressure therapy.

Glucose-dependent insulinotropic polypeptide (GIP) acts as a bifunctional blood sugar stabilizing factor in type 2 diabetes.

GIP may be considered in therapeutic strategies for managing blood sugar in type 2 diabetes.